GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first ...

Auto parts-maker targets 8% annual growth by 2027, vows to diversify clientele beyond Hyundai, Kia Korea’s leading ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...